Literature DB >> 23296391

Spondyloarthritis in 2012: Advances in pathogenesis through animal models and imaging.

Walter P Maksymowych1.   

Abstract

Advances in 2012 have helped to solve several established mysteries in spondyloarthritis (SpA) - why T-cell-directed therapies have not delivered the expected efficacy and how the IL-23-IL-17 cytokine axis is linked to the specific pathology of SpA. The opportunity to influence disease progression at inflammatory lesions using anti-TNF agents may be fleeting.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296391     DOI： 10.1038/nrrheum.2012.233

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis.

Authors:  Tony J Kenna; Stuart I Davidson; Ran Duan; Linda A Bradbury; Janelle McFarlane; Malcolm Smith; Helen Weedon; Shayna Street; Ranjeny Thomas; Gethin P Thomas; Matthew A Brown
Journal:  Arthritis Rheum       Date:  2012-05

2.  Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.

Authors:  Walter P Maksymowych; Nathalie Morency; Barbara Conner-Spady; Robert G Lambert
Journal:  Ann Rheum Dis       Date:  2012-05-05       Impact factor: 19.103

3.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies.

Authors:  D Kontoyiannis; M Pasparakis; T T Pizarro; F Cominelli; G Kollias
Journal:  Immunity       Date:  1999-03       Impact factor: 31.745

Review 4.  Progress in the genetics of ankylosing spondylitis.

Authors:  Matthew A Brown
Journal:  Brief Funct Genomics       Date:  2011-09-30       Impact factor: 4.241

5.  Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis.

Authors:  Troy Noordenbos; Nataliya Yeremenko; Ioana Gofita; Marleen van de Sande; Paul P Tak; Juan D Caňete; Dominique Baeten
Journal:  Arthritis Rheum       Date:  2012-01

6.  Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study.

Authors:  I-H Song; F Heldmann; M Rudwaleit; H Haibel; A Weiss; J Braun; J Sieper
Journal:  Ann Rheum Dis       Date:  2011-03-17       Impact factor: 19.103

7.  β-glucan triggers spondylarthritis and Crohn's disease-like ileitis in SKG mice.

Authors:  Merja Ruutu; Gethin Thomas; Roland Steck; Mariapia A Degli-Esposti; Martin S Zinkernagel; Kylie Alexander; Jared Velasco; Geoffrey Strutton; Ai Tran; Helen Benham; Linda Rehaume; Robert J Wilson; Kristine Kikly; Julian Davies; Allison R Pettit; Matthew A Brown; Michael A McGuckin; Ranjeny Thomas
Journal:  Arthritis Rheum       Date:  2012-07

8.  Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis.

Authors:  Hui Shen; Jane C Goodall; J S Hill Gaston
Journal:  Arthritis Rheum       Date:  2009-06

9.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells.

Authors:  Jonathan P Sherlock; Barbara Joyce-Shaikh; Scott P Turner; Cheng-Chi Chao; Manjiri Sathe; Jeff Grein; Daniel M Gorman; Edward P Bowman; Terrill K McClanahan; Jennifer H Yearley; Gérard Eberl; Christopher D Buckley; Robert A Kastelein; Robert H Pierce; Drake M Laface; Daniel J Cua
Journal:  Nat Med       Date:  2012-07-01       Impact factor: 53.440

10.  Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response.

Authors:  Heiner Appel; René Maier; Peihua Wu; Rebecca Scheer; Axel Hempfing; Ralph Kayser; Andreas Thiel; Andreas Radbruch; Christoph Loddenkemper; Joachim Sieper
Journal:  Arthritis Res Ther       Date:  2011-06-20       Impact factor: 5.156
  10 in total
  1 in total

1.  Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab.

Authors:  Jeong Seok Lee; Yeong Wook Song; Tae Hwan Kim; Won Tae Chung; Seung Geun Lee; Sung Hwan Park; Gwan Gyu Song; Dae Young Yu; Stephen Xu; Eun Young Lee
Journal:  Korean J Intern Med       Date:  2017-01-20       Impact factor: 2.884
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.